ASTEX PHARMACEUTICALS, INC Clinical Trials
Studies registered on ClinicalTrials.gov (U.S. National Library of Medicine) with the company as lead sponsor or collaborator, newest start first. Values are as registered.
- 2025-02-07: Study NCT06802146; Company role Collaborator; Phase Early Phase 1; Status Recruiting.
- 2024-07-01: Study NCT06297629; Company role Collaborator; Phase Phase 2; Status Withdrawn.
- 2024-03-07: Study NCT06191978; Company role Collaborator; Phase Phase 1; Status Recruiting.
- 2023-06-27: Study NCT05835011; Company role Lead sponsor; Phase Phase 2; Status Terminated.
| Start date | Study | Company role | Phase | Status | Conditions | Enrollment | Completion date |
|---|---|---|---|---|---|---|---|
| 2025-02-07 | NCT06802146 Early Intervention in High Risk CCUS | Collaborator Lead: Lachelle D. Weeks, MD, PhD | Early Phase 1 | Recruiting | Clonal Cytopenia of Undetermined Significance; Cytopenia | 108 | 2028-12-01 |
| 2024-07-01 | NCT06297629 A Phase I/II Trial to Assess the Efficacy and Toxicity of ASTX727 (Oral Decitabine/Cedazuridine) for the Treatment of Hematological Neoplasms After Allogeneic Stem Cell Transplantation | Collaborator Lead: M.D. Anderson Cancer Center | Phase 2 | Withdrawn | Allogeneic Stem Cell Transplantation | 0 | 2024-07-11 |
| 2024-03-07 | NCT06191978 A Phase Ia/Ib Open-label, Multiple Dose, Study to Determine the Recommended Dose, Evaluate PKs, PDs, Safety, and Activity of Venetoclax in Combination With Oral Decitabine/Cedazuridine (ASTX727) in Pediatric Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) | Collaborator Lead: M.D. Anderson Cancer Center | Phase 1 | Recruiting | Acute Myeloid Leukemia | 40 | 2028-12-31 |
| 2023-06-27 | NCT05835011 A Study of Oral Decitabine/Cedazuridine in Combination With Magrolimab in Participants With Intermediate- to Very High-Risk Myelodysplastic Syndromes (MDS) | Lead sponsor | Phase 2 | Terminated Results posted | Myelodysplastic Syndromes | 2 | 2023-08-21 |
| 2022-10-14 | NCT05360160 A Phase I-II Study Investigating the All-Oral Combination of the Menin Inhibitor SNDX-5613 With Decitabine/Cedazuridine (ASTX727) and Venetoclax in Acute Myeloid Leukemia (SAVE) | Collaborator Lead: M.D. Anderson Cancer Center | Phase 1, Phase 2 | Recruiting | Acute Myeloid Leukemia | 43 | 2026-12-01 |
| 2022-07-29 | NCT05456269 A Study of Bisantrene Combined With Cytarabine or With Decitabine for Adult Subjects With Extramedullary AML and MDS | Collaborator Lead: Racura Oncology Ltd | Phase 1 | Withdrawn | Acute Myeloid Leukemia; Recurrent Acute Myeloid Leukemia; Refractory Acute Myeloid Leukemia; Higher Risk Myelodysplastic Syndrome; Chronic Myelomonocytic Leukemia | 0 | 2023-08-31 |
| 2022-03-02 | NCT05082259 ASTEROID: A Trial of ASTX660 in Combination With Pembrolizumab | Collaborator Lead: Institute of Cancer Research, United Kingdom | Phase 1 | Active not recruiting | Advanced Cancer; Cervical Cancer; Triple Negative Breast Cancer | 61 | 2026-12 |
| 2022-02-17 | NCT05245682 Tolinapant and Radiation for Cisplatin-Ineligible, Previously Untreated, Locally Advanced Head and Neck Cancer | Collaborator Lead: Emory University | Early Phase 1 | Active not recruiting Results posted | Head and Neck Carcinoma of Unknown Primary; Locally Advanced Head and Neck Squamous Cell Carcinoma; Locally Advanced Hypopharyngeal Squamous Cell Carcinoma; Locally Advanced Laryngeal Squamous Cell Carcinoma; Locally Advanced Nasopharyngeal Squamous Cell Carcinoma; Locally Advanced Oropharyngeal Squamous Cell Carcinoma | 10 | 2027-07-21 |
| 2021-11-24 | NCT04061421 Active Myeloid Target Compound Combinations in MDS/MPN Overlap Syndromes Overlap Syndromes (ABNL-MARRO) | Collaborator Lead: Michael Savona | Phase 1, Phase 2 | Recruiting | MDS/MPN | 94 | 2027-12 |
| 2021-10-21 | NCT05007873 ASTX727 and Dasatinib for the Treatment of Newly Diagnosed Philadelphia Chromosome or BCR-ABL Positive Chronic Myeloid Leukemia in Chronic Phase | Collaborator Lead: M.D. Anderson Cancer Center | Phase 2 | Active not recruiting | Chronic Phase Chronic Myelogenous Leukemia; Philadelphia Chromosome Positive; BCR-ABL1 Positive Chronic Myelogenous Leukemia; BCR-ABL1 Positive | 39 | 2026-10-30 |
| 2021-07-01 | NCT04953923 Thorough QT Assessment of Cedazuridine in Healthy Subjects | Lead sponsor | Phase 1 | Completed | Healthy Volunteers | 36 | 2021-11-16 |
| 2021-06-22 | NCT04857645 ASTX727 and Donor Lymphocyte Infusions After Allogenic Stem Cell Transplantation in Very High Risk MDS or AML Patients | Collaborator Lead: Groupe Francophone des Myelodysplasies | Phase 2 | Completed | MDS; AML | 57 | 2025-04-22 |
| 2021-01-19 | NCT04655755 Venetoclax in Combination With ASTX727 for the Treatment of Treatment-Naive High-Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia | Collaborator Lead: M.D. Anderson Cancer Center | Phase 1, Phase 2 | Active not recruiting | Chronic Myelomonocytic Leukemia; Myelodysplastic Syndrome | 52 | 2028-07-20 |
| 2020-12-21 | NCT04637009 A Study of TAS1553 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia (AML) and Other Myeloid Neoplasms | Lead sponsor | Phase 1 | Terminated | Acute Myeloid Leukemia; Myeloproliferative Neoplasm; Myelodysplastic/Myeloproliferative Neoplasm | 20 | 2023-02-20 |
| 2020-07-23 | NCT04466514 A Phase 1 Study to Evaluate the Effect of Food on Pharmacokinetics of ASTX029 | Lead sponsor | Phase 1 | Completed | Healthy Volunteers | 18 | 2020-10-06 |
| 2020-07-20 | NCT04479800 Effect of Food on the Pharmacokinetics of ASTX660 in Healthy Volunteers | Lead sponsor | Phase 1 | Completed | Healthy Volunteer | 21 | 2020-08-25 |
| 2020-06-12 | NCT04155580 A Study of ASTX660 as a Single Agent and in Combination With ASTX727 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia (AML) | Lead sponsor | Phase 1 | Terminated | Acute Myeloid Leukemia | 68 | 2022-01-14 |
| 2020-05-20 | NCT04411030 A Study to Investigate the Effect of CYP3A4 Inhibition on the Single Dose Pharmacokinetics of ASTX660 and the Effect of a Single Dose of ASTX660 on the Pharmacokinetics of the CYP3A4 Substrate Midazolam | Lead sponsor | Phase 1 | Completed | Healthy Volunteer | 36 | 2020-08-29 |
| 2020-04-01 | NCT04134884 Study of ASTX727 Plus Talazoparib in Patients With Triple Negative or Hormone Resistant/HER2-negative Metastatic Breast Cancer | Collaborator Lead: Kathy Miller | Phase 1 | Completed | Metastatic Breast Cancer; Triple Negative Breast Cancer; Hormone Receptor Positive Tumor | 34 | 2024-03-14 |
| 2020-03 | NCT04250246 A Study of NIVO Plus IPI and Guadecitabine or NIVO Plus IPI in Melanoma and NSCLC Resistant to Anti-PD1/PDL1 | Collaborator Lead: Italian Network for Tumor Biotherapy Foundation | Phase 2 | Unknown | Melanoma; Non Small Cell Lung Cancer | 184 | 2025-03 |
| 2020-01-30 | NCT03576963 Guadecitabine and Nivolumab in Treating Refractory Metastatic Colorectal Cancer | Collaborator Lead: University of Southern California | Phase 1, Phase 2 | Withdrawn | Colorectal Adenocarcinoma; CpG Island Methylator Phenotype; Metastatic Microsatellite Stable Colorectal Carcinoma; Refractory Colorectal Carcinoma; Stage IV Colorectal Cancer AJCC v8; Stage IVA Colorectal Cancer AJCC v8; Stage IVB Colorectal Cancer AJCC v8; Stage IVC Colorectal Cancer AJCC v8 | 0 | 2023-01-30 |
| 2019-08-27 | NCT04013880 ASTX727 and FT-2102 in Treating IDH1-Mutated Recurrent/Refractory Myelodysplastic Syndrome or Acute Myeloid Leukemia | Collaborator Lead: Vanderbilt-Ingram Cancer Center | Phase 1, Phase 2 | Withdrawn | Acute Myeloid Leukemia; Myelodysplastic Syndrome; Recurrent Acute Myeloid Leukemia; Recurrent Myelodysplastic Syndrome; Refractory Acute Myeloid Leukemia; Refractory Myelodysplastic Syndrome | 0 | 2022-03-31 |
| 2019-07-12 | NCT03922555 ASTX727 in Recurrent/Progressive Non-enhancing IDH Mutant Gliomas | Collaborator Lead: Massachusetts General Hospital | Phase 1 | Recruiting | Neurological Cancer | 18 | 2028-08-01 |
| 2019-06-06 | NCT03913455 Guadecitabine in Combination With Carboplatin in Extensive Stage Small Cell Lung Cancer | Collaborator Lead: Shadia Jalal, MD | Phase 2 | Completed Results posted | Small Cell Lung Cancer; Extensive-stage Small Cell Lung Cancer | 24 | 2022-02-02 |
| 2019-04-17 | NCT03875287 Dose-Escalation Study of E7727, an Oral Cytidine Deaminase Inhibitor With Oral Decitabine in Subjects With Solid Tumors | Collaborator Lead: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Phase 1 | Active not recruiting | Solid Tumor | 35 | 2027-09-01 |
| 2018-11-08 | NCT03813186 Effect of Food on Blood Levels of ASTX727 | Lead sponsor | Phase 1 | Completed | Myelodysplastic Syndromes; Chronic Myelomonocytic Leukemia; Acute Myeloid Leukemia | 18 | 2019-12-16 |
| 2018-07-18 | NCT03603964 Guadecitabine Extension Study | Lead sponsor | Phase 2 | Terminated Results posted | Acute Myeloid Leukemia; Myeloid Dysplastic Syndrome | 35 | 2021-10-04 |
| 2018-02-15 | NCT03306264 Study of ASTX727 vs IV Decitabine in Participants With MDS, CMML, and AML | Lead sponsor | Phase 3 | Completed Results posted | Myelodysplastic Syndromes; Chronic Myelomonocytic Leukemia; Acute Myeloid Leukemia | 227 | 2023-05-25 |
| 2017-08-04 | NCT03220477 Pembrolizumab (Immunotherapy Drug) in Combination With Guadecitabine and Mocetinostat (Epigenetic Drugs) for Patients With Advanced Lung Cancer. | Collaborator Lead: Memorial Sloan Kettering Cancer Center | Phase 1 | Active not recruiting | Lung Cancer | 28 | 2027-07 |
| 2017-03-20 | NCT03019003 Oral Decitabine (ASTX727) and Durvalumab in Recurrent and/or Metastatic Head and Neck Cancer Patients | Collaborator Lead: Massachusetts General Hospital | Phase 1 | Completed Results posted | Head and Neck Cancer | 13 | 2024-09-24 |
| 2017-03-16 | NCT02920008 Phase 3 Randomized, Open-Label Study of Guadecitabine vs Treatment Choice in Previously Treated Acute Myeloid Leukemia | Lead sponsor | Phase 3 | Completed Results posted | Acute Myeloid Leukemia | 302 | 2020-06-01 |
| 2017-01-26 | NCT02998567 Combination Study of Guadecitabine/ASTX727 and Pembrolizumab | Collaborator Lead: Royal Marsden NHS Foundation Trust | Phase 1 | Active not recruiting | Non Small Cell Lung Cancer | 60 | 2026-09 |
| 2017-01-13 | NCT02907359 Guadecitabine (SGI-110) vs Treatment Choice in Adults With MDS or CMML Previously Treated With HMAs | Lead sponsor | Phase 3 | Completed Results posted | Myelodysplastic Syndromes; Leukemia, Myelomonocytic, Chronic | 417 | 2020-11-30 |
| 2016-11-11 | NCT02901899 Guadecitabine and Pembrolizumab in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer | Collaborator Lead: Northwestern University | Phase 2 | Completed Results posted | Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma | 45 | 2023-03-31 |
| 2016-03-15 | NCT03075826 A Phase II Study of SGI-110 in Philadelphia-Negative Myeloproliferative Neoplasms | Collaborator Lead: Weill Medical College of Cornell University | Phase 2 | Completed Results posted | Myeloproliferative Neoplasms | 22 | 2021-03-31 |
| 2015-10 | NCT02608437 A Study Investigating SGI-110 in Combination With Ipilimumab in Unresectable or Metastatic Melanoma Patients | Collaborator Lead: Italian Network for Tumor Biotherapy Foundation | Phase 1 | Unknown | Metastatic Melanoma | 19 | 2018-10 |
| 2015-03-19 | NCT02348489 SGI-110 in Adults With Untreated Acute Myeloid Leukemia (AML), Not Considered Candidates for Intensive Remission Induction | Lead sponsor | Phase 3 | Completed Results posted | Leukemia, Myeloid, Acute | 815 | 2019-06-17 |
| 2014-10-28 | NCT02103478 Pharmacokinetic Guided Dose Escalation and Dose Confirmation With Oral Decitabine and Oral Cytidine Deaminase Inhibitor (CDAi) in Patients With Myelodysplastic Syndromes (MDS) | Lead sponsor | Phase 1, Phase 2 | Completed Results posted | Myelodysplastic Syndrome; MDS | 130 | 2019-12-04 |
| 2014-08-04 | NCT02197676 A Phase II Trial of SGI-110 in Patients With IPSS High and Int 2 Myelodysplastic Syndrome, Acute Myeloid Leukemia With 20-30% Marrow Blasts or Chronic Myelomonocytic Leukemia Type 2 Not Responding to Azacitidine or Decitabine After at Least 6 Courses or Relapsing After a Response | Collaborator Lead: Groupe Francophone des Myelodysplasies | Phase 2 | Completed | MDS | 56 | 2018-04-23 |
| 2013-10-23 | NCT01896856 Phase I/II Study of SGI-110 With Irinotecan Versus Regorafenib or TAS-102 in Metastatic Colorectal Cancer | Collaborator Lead: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Phase 1, Phase 2 | Completed Results posted | Previously Treated Metastatic Colorectal Cancer | 118 | 2019-08-26 |
| 2012-12 | NCT01752933 SGI-110 in the Treatment of Advanced Hepatocellular Carcinoma (HCC) | Lead sponsor | Phase 2 | Completed Results posted | Hepatocellular Carcinoma | 52 | 2015-09 |
| 2012-10 | NCT01712217 A Study of AT13387 in Patients With Non-Small Cell Lung Cancer (NSCLC) Alone and in Combination With Crizotinib | Lead sponsor | Phase 1, Phase 2 | Completed | Non-small Cell Lung Cancer(NSCLC) | 220 | 2017-05-16 |
| 2012-09-14 | NCT01652144 A Phase II Study of AT7519M, a CDK Inhibitor, in Patients With Relapsed Mantle Cell Lymphoma | Collaborator Lead: NCIC Clinical Trials Group | Phase 2 | Completed | Mantle Cell Lymphoma | 12 | 2015-02-13 |
| 2012-09 | NCT01696032 SGI-110 in Combination With Carboplatin in Ovarian Cancer | Lead sponsor | Phase 2 | Completed Results posted | Ovarian Cancer | 120 | 2016-08 |
| 2012-09 | NCT01685268 A Study of HSP90 Inhibitor AT13387 Alone or in Combination With Abiraterone Acetate | Lead sponsor | Phase 1, Phase 2 | Completed | Prostate Cancer | 49 | 2014-12 |
| 2012-08-27 | NCT01627054 A Phase II Study of AT7519M, a CDK Inhibitor, in Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia | Collaborator Lead: NCIC Clinical Trials Group | Phase 2 | Completed | Chronic Lymphocytic Leukemia | 7 | 2015-02-13 |
| 2011-05 | NCT01357395 A Phase 2, Open-Label Study of Amuvatinib in Combination With Platinum-Etoposide Chemotherapy in Small Cell Lung Cancer | Lead sponsor | Phase 2 | Completed | Small Cell Lung Carcinoma | 23 | 2012-05-28 |
| 2011-03 | NCT01294202 A Study to Investigate the Safety and Efficacy of AT13387, Alone or in Combination With Imatinib, in Patients With GIST | Lead sponsor | Phase 2 | Completed | Gastrointestinal Stromal Tumor (GIST) | 26 | 2014-07 |
| 2011-02-15 | NCT01145989 A Study of AT9283 in Patients With Relapsed or Refractory Multiple Myeloma | Collaborator Lead: NCIC Clinical Trials Group | Phase 2 | Completed | Multiple Myeloma | 8 | 2015-11-27 |
| 2011-01-04 | NCT01261312 SGI-110 in Participants With Myelodysplastic Syndromes (MDS) or Acute Myelogenous Leukemia (AML) | Lead sponsor | Phase 1, Phase 2 | Completed Results posted | MDS; CMML; AML | 414 | 2016-07-22 |
| 2010-11 | NCT01183949 Effect of AT7519M Alone and AT7519M Plus Bortezomib in Patients With Previously Treated Multiple Myeloma | Lead sponsor | Phase 1, Phase 2 | Completed | Multiple Myeloma | 18 | 2015-03 |
| 2010-10 | NCT01239108 Study of SGI-1776, a PIM Kinase Inhibitor, in Subjects With Relapsed/Refractory Leukemias | Lead sponsor | Phase 1 | Withdrawn | Relapsed/Refractory Leukemias | 0 | 2012-04 |
| 2009-02 | NCT00848601 Safety of SGI-1776, A PIM Kinase Inhibitor in Refractory Prostate Cancer and Relapsed/Refractory Non Hodgkin's Lymphoma | Lead sponsor | Phase 1 | Terminated | Prostate Cancer; Non-Hodgkins Lymphoma | 14 | 2010-10 |
| 2008-05 | NCT00878423 Study to Assess the Safety of Escalating Doses of AT13387 in Patients With Metastatic Solid Tumors | Lead sponsor | Phase 1 | Completed | Metastatic Solid Tumors | 62 | 2014-03 |
| 2007-11 | NCT00881166 Safety of MP470 in Combination With Standard-of-Care Chemotherapy Regimens to Treat Solid Tumors | Lead sponsor | Phase 1 | Completed | Malignant Disease | 101 | 2009-12 |
| 2007-05 | NCT00894894 Safety Study to Determine the Maximum Tolerated Dose, Pharmacokinetics and Pharmacodynamics of Oral MP470, a Multitargeted Tyrosine Kinase Inhibitor, in Patients With Solid Malignancies | Lead sponsor | Phase 1 | Completed | Solid Tumors | 22 | 2008-12 |
| 2007-05 | NCT00504205 MP470 in Treating Patients With Unresectable or Metastatic Solid Tumor or Lymphoma | Lead sponsor | Not applicable | Terminated | Lymphoma; Unspecified Adult Solid Tumor, Protocol Specific | 30 | 2010-03 |
| 2007-01-30 | NCT00443976 Aurora Kinase Inhibitor AT9283 in Treating Patients With Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma | Collaborator Lead: NCIC Clinical Trials Group | Phase 1 | Completed | Non-Hodgkins Lymphoma; Unspecified Adult Solid Tumor, Protocol Specific | 35 | 2012-01-06 |
| 2006-09 | NCT00522990 Study to Assess the Safety of Escalating Doses of AT9283, in Patients With Leukemias | Lead sponsor | Phase 1, Phase 2 | Terminated | Acute Myeloid Leukemia; Acute Lymphoblastic Leukemia; Chronic Myeloid Leukemia; Myelodysplastic Syndromes; Myelofibrosis | 48 | 2009-04 |
| 2005-06 | NCT00496873 Evaluation of the Safety and Efficacy of Nipent, Cytoxan, and Rituxan | Collaborator Lead: M.D. Anderson Cancer Center | Phase 2 | Completed Results posted | Lymphoma | 100 | 2014-12 |
| 2005-05 | NCT00541034 Pentostatin, Cyclophosphamide, and Rituximab in Treating Patients With Previously Untreated Chronic Lymphocytic Leukemia | Collaborator Lead: Memorial Sloan Kettering Cancer Center | Phase 2 | Completed Results posted | Leukemia; Lymphoma | 49 | 2016-01 |
| 2005-02 | NCT00113256 Orathecin + Gemcitabine Versus Placebo + Gemcitabine in Chemonaive Non-Resectable Pancreatic Cancer | Lead sponsor | Phase 2, Phase 3 | Terminated | Pancreatic Cancer | 39 | |
| 2004-09 | NCT00453193 Alemtuzumab and Pentostatin In T-cell Neoplasms | Collaborator Lead: M.D. Anderson Cancer Center | Phase 2 | Terminated Results posted | Lymphoma; Leukemia | 26 | 2010-03 |
| 2004-01 | NCT00144430 Pentostatin for High Risk and Refractory Chronic Graft Versus Host Disease in Children | Collaborator Lead: Ann & Robert H Lurie Children's Hospital of Chicago | Phase 2 | Completed | Graft vs Host Disease | 60 | 2008-08 |
| 2003-12 | NCT00254163 Fludarabine, Cyclophosphamide, and Rituximab Versus Pentostatin, Cyclophosphamide, and Rituximab in Previously Untreated or Treated B-Cell Chronic Lymphocytic Leukemia Patients | Collaborator Lead: US Oncology Research | Phase 3 | Completed Results posted | B-Cell Chronic Lymphocytic Leukemia | 184 | 2011-09 |
| 2003-01 | NCT00131313 Efficacy and Safety of Nipent, Cytoxan and Rituxan in the Treatment of Chronic Lymphocytic Leukemia. | Collaborator Lead: East Valley Hematology and Oncology Medical Group | Phase 4 | Unknown | Chronic Lymphocytic Leukemia | 180 | 2009-04 |
| 2002-07 | NCT00201721 Pentostatin, and Rituximab With and Without Cyclophosphamide for Previously Untreated B-Chronic Lymphocytic Leukemia | Collaborator Lead: Ohio State University Comprehensive Cancer Center | Phase 2 | Completed | B-Chronic Lymphocytic Leukemia | 28 | 2006-09 |
| 2002-07 | NCT00042016 Phase II Trial of Decitabine in Patients With Chronic Myelogenous Leukemia Chronic Phase Who Are Refractory to Imatinib Mesylate (Gleevec) | Lead sponsor | Phase 2 | Completed | Chronic Myelogenous Leukemia | 40 | |
| 2002-07 | NCT00042003 Phase II Trial of Decitabine in Patients With Chronic Myelogenous Leukemia Blast Phase Who Are Refractory to Imatinib Mesylate (Gleevec) | Lead sponsor | Phase 2 | Completed | Chronic Myelogenous Leukemia | 40 | |
| 2002-07 | NCT00041990 Phase II Trial of Decitabine in Patients With Chronic Myelogenous Leukemia Accelerated Phase Who Are Refractory to Imatinib Mesylate (Gleevec) | Lead sponsor | Phase 2 | Completed | Chronic Myelogenous Leukemia | 40 | |
| 2002-01-30 | NCT00032773 Dose-finding Study Using Pentostatin for Injection in the Treatment of Steroid-refractory aGvHD | Lead sponsor | Phase 1, Phase 2 | Terminated | Acute Graft Versus Host Disease | 36 | 2005-11-03 |
| 2001-08 | NCT00113113 Study of Rubitecan in Cancer Patients With Renal or Hepatic Dysfunction | Lead sponsor | Phase 1 | Completed | Tumors | 54 | |
| 2001-04 | NCT00043381 Decitabine Versus Supportive Care in Adults With Advanced-stage MDS | Lead sponsor | Phase 3 | Completed | Myelodysplastic Syndrome | 160 | 2003-04 |
| 2000-12-08 | NCT00571662 Safety and Efficacy of Pentostatin and Low Dose TBI With Allogenic Peripheral Blood Stem Cell Transplant | Collaborator Lead: University of Nebraska | Phase 2 | Completed Results posted | Acute Myelogenous Leukemia; Acute Lymphocytic Leukemia; Chronic Myelogenous Leukemia; Chronic Lymphocytic Leukemia; Myelodysplastic Syndromes; Multiple Myeloma; Non-Hodgkins Lymphoma; Hodgkins Disease; Peripheral T-cell Lymphoma | 76 | 2008-12-30 |
| 2000-09 | NCT00506922 Phase I/II Study of Pentostatin Combined With Tacrolimus and Mini-Methotrexate for GVHD Prevention After MUD BMT | Collaborator Lead: M.D. Anderson Cancer Center | Phase 1, Phase 2 | Completed Results posted | Leukemia; Lymphoma | 150 | 2009-11 |
| 2000-06 | NCT00006047 Combination Therapy With Oral 9-Nitrocamptothecin & Oral Etoposide | Collaborator Lead: H. Lee Moffitt Cancer Center and Research Institute | Phase 1 | Completed | Unspecified Adult Solid Tumor, Protocol Specific | 44 | 2003-02 |
| 2000-04 | NCT00005876 Nitrocamptothecin in Treating Patients With Locally Advanced or Metastatic Stomach Cancer That Cannot Be Removed During Surgery | Lead sponsor | Phase 2 | Unknown | Esophageal Cancer; Gastric Cancer | ||
| 1999-09 | NCT00005877 Nitrocamptothecin in Treating Patients With Advanced or Recurrent Colorectal Cancer | Lead sponsor | Phase 2 | Unknown | Colorectal Cancer | ||
| 1999-09 | NCT00005873 Nitrocamptothecin in Treating Patients With Locally Recurrent or Metastatic Breast Cancer | Lead sponsor | Phase 2 | Completed | Breast Cancer | 2004-04 | |
| 1999-06 | NCT00005874 Nitrocamptothecin in Treating Patients With Soft Tissue Sarcomas | Lead sponsor | Phase 2 | Completed | Gastrointestinal Stromal Tumor; Sarcoma; Small Intestine Cancer | 2004-04 | |
| 1999-05 | NCT00005872 Nitrocamptothecin in Treating Patients With Recurrent Non-small Cell Lung Cancer | Lead sponsor | Phase 2 | Completed | Lung Cancer | 2004-04 | |
| 1999-03 | NCT00005870 Nitrocamptothecin Compared With Other Chemotherapy in Treating Patients With Recurrent or Refractory Cancer of the Pancreas | Lead sponsor | Phase 3 | Unknown | Pancreatic Cancer | ||
| 1999-01 | NCT00005875 Nitrocamptothecin in Treating Patients With Metastatic Melanoma | Lead sponsor | Phase 2 | Completed | Melanoma (Skin) | 2004-04 | |
| 1998-11 | NCT00005871 Nitrocamptothecin or Fluorouracil in Treating Patients With Recurrent or Refractory Pancreatic Cancer | Lead sponsor | Phase 3 | Unknown | Pancreatic Cancer | ||
| 1998-11 | NCT00005869 Nitrocamptothecin Compared With Gemcitabine in Treating Patients With Unresectable Locally Advanced or Metastatic Pancreatic Cancer | Lead sponsor | Phase 3 | Unknown | Pancreatic Cancer |